These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26763003)

  • 21. Clinical impact and management of fluconazole discontinuation on sirolimus levels in bone marrow transplant patients.
    Nwaroh E; Jupp J; Jadusingh E; Guilcher G
    J Oncol Pharm Pract; 2018 Apr; 24(3):235-238. PubMed ID: 28355970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
    Khaled SK; Palmer JM; Herzog J; Stiller T; Tsai NC; Senitzer D; Liu X; Thomas SH; Shayani S; Weitzel J; Forman SJ; Nakamura R
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):268-276. PubMed ID: 26325438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an update.
    Cutler C; Antin JH
    Curr Opin Hematol; 2010 Nov; 17(6):500-4. PubMed ID: 20717025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.
    Cutler C; Li S; Kim HT; Laglenne P; Szeto KC; Hoffmeister L; Harrison MJ; Ho V; Alyea E; Lee SJ; Soiffer R; Sonis S; Antin JH
    Biol Blood Marrow Transplant; 2005 May; 11(5):383-8. PubMed ID: 15846292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.
    Luu Tran H; Mahmoudjafari Z; Rockey M; Henry D; Grauer D; Aljitawi O; Abhyankar S; Ganguly S; Lin T; McGuirk J
    J Oncol Pharm Pract; 2016 Apr; 22(2):228-34. PubMed ID: 25471252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
    Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease.
    Jurado M; Vallejo C; Pérez-Simón JA; Brunet S; Ferra C; Balsalobre P; Pérez-Oteyza J; Espigado I; Romero A; Caballero D; Sierra J; Ribera JM; Díez JL
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):701-6. PubMed ID: 17531780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids.
    Pidala J; Tomblyn M; Nishihori T; Field T; Ayala E; Perkins J; Fernandez H; Locke F; Perez L; Ochoa JL; Alsina M; Anasetti C
    Haematologica; 2011 Sep; 96(9):1351-6. PubMed ID: 21565902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug interaction between letermovir and voriconazole after allogeneic hematopoietic cell transplantation.
    Nakashima T; Inamoto Y; Fukushi Y; Doke Y; Hashimoto H; Fukuda T; Yamaguchi M
    Int J Hematol; 2021 Jun; 113(6):872-876. PubMed ID: 33677768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Fatal zygomycosis caused by Mucor indicus after haplo-identical stem cell transplantation].
    Koteda S; Nomura K; Hashiguchi M; Kawaguchi K; Oku E; Osaki K; Nakamura T; Mouri F; Imamura R; Seki R; Nagafuji K; Makimura K; Okamura T
    Rinsho Ketsueki; 2013 Mar; 54(3):311-5. PubMed ID: 23676649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
    Cutler C; Kim HT; Hochberg E; Ho V; Alyea E; Lee SJ; Fisher DC; Miklos D; Levin J; Sonis S; Soiffer RJ; Antin JH
    Biol Blood Marrow Transplant; 2004 May; 10(5):328-36. PubMed ID: 15111932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study.
    Schleuning M; Judith D; Jedlickova Z; Stübig T; Heshmat M; Baurmann H; Schwerdtfeger R
    Bone Marrow Transplant; 2009 May; 43(9):717-23. PubMed ID: 19011660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calcineurin inhibitor-free graft-versus-host disease prophylaxis with sirolimus and mycophenolate mofetil in a second allogeneic stem cell transplantation for engraftment failure and rituximab-refractory Epstein-Barr virus-induced posttransplant lymphoproliferative disease.
    Ceppi F; Duval M; Teira P; Therrien R; Ovetchkine P; Mallette B; Bittencourt H
    J Pediatr Hematol Oncol; 2014 Jul; 36(5):e319-21. PubMed ID: 24977404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple drug interactions with cyclosporine in a heart transplant patient.
    Zylber-Katz E
    Ann Pharmacother; 1995 Feb; 29(2):127-31. PubMed ID: 7756709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders.
    Ringdén O; Remberger M; Dahllöf G; Garming-Legert K; Karlsson H; Svenberg P; Uhlin M; Uzunel M; Mattsson J
    Eur J Haematol; 2011 Dec; 87(6):503-9. PubMed ID: 22974354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis.
    Siwek GT; Dodgson KJ; de Magalhaes-Silverman M; Bartelt LA; Kilborn SB; Hoth PL; Diekema DJ; Pfaller MA
    Clin Infect Dis; 2004 Aug; 39(4):584-7. PubMed ID: 15356827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease.
    Johnston LJ; Brown J; Shizuru JA; Stockerl-Goldstein KE; Stuart MJ; Blume KG; Negrin RS; Chao NJ
    Biol Blood Marrow Transplant; 2005 Jan; 11(1):47-55. PubMed ID: 15625544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Voriconazole exposure and the risk of cutaneous squamous cell carcinoma in allogeneic hematopoietic stem cell transplant patients.
    Wojenski DJ; Bartoo GT; Merten JA; Dierkhising RA; Barajas MR; El-Azhary RA; Wilson JW; Plevak MF; Hogan WJ; Litzow MR; Patnaik MM; Wolf RC; Hashmi SK
    Transpl Infect Dis; 2015 Apr; 17(2):250-8. PubMed ID: 25661996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation.
    Claxton DF; Ehmann C; Rybka W
    Br J Haematol; 2005 Jul; 130(2):256-64. PubMed ID: 16029454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.
    Iwamoto T; Monma F; Fujieda A; Nakatani K; Katayama N; Okuda M
    Clin Ther; 2011 Aug; 33(8):1077-80. PubMed ID: 21802143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.